Medical Research Council/Uganda Virus Research Institute-Uganda Research Unit on AIDS, Entebbe, Uganda.
Clin Infect Dis. 2010 Feb 15;50(4):531-40. doi: 10.1086/649924.
Helminth infections during pregnancy may be associated with adverse outcomes, including maternal anemia, low birth weight, and perinatal mortality. Deworming during pregnancy has therefore been strongly advocated, but its benefits have not been rigorously evaluated.
In Entebbe, Uganda, 2507 pregnant women were recruited to a randomized, double-blind, placebo-controlled trial investigating albendazole and praziquantel in a 2 x 2 factorial design [ISRCTN32849447]. Hematinics and sulphadoxine-pyrimethamine for presumptive treatment of malaria were provided routinely. Maternal and perinatal outcomes were recorded. Analyses were by intention to treat.
At enrollment, 68% of women had helminths, 45% had hookworm, 18% had Schistosoma mansoni infection; 40% were anemic (hemoglobin level, <11.2 g/dL). At delivery, 35% were anaemic; there was no overall effect of albendazole (odds ratio [OR], 0.95; 95% confidence interval [CI], 0.79-1.15) or praziquantel (OR, 1.00; 95% CI, 0.83-1.21) on maternal anemia, but there was a suggestion of benefit of albendazole among women with moderate to heavy hookworm (OR, 0.45; 95% CI, 0.21-0.98; P=.15 for interaction). There was no effect of either anthelminthic treatment on mean birth weight (difference in mean associated with albendazole: -0.00 kg; 95% CI, -0.05 to 0.04 kg; difference in mean associated with praziquantel: -0.01 kg; 95% CI, -0.05 to 0.04 kg) or on proportion of low birth weight. Anthelminthic use during pregnancy showed no effect on perinatal mortality or congenital anomalies.
In our study area, where helminth prevalence was high but infection intensity was low, there was no overall effect of anthelminthic use during pregnancy on maternal anemia, birth weight, perinatal mortality, or congenital anomalies. The possible benefit of albendazole against anemia in pregnant women with heavy hookworm infection warrants further investigation.
怀孕期间的寄生虫感染可能与不良结局相关,包括母体贫血、低出生体重和围产期死亡。因此,强烈提倡在怀孕期间驱虫,但驱虫的益处尚未经过严格评估。
在乌干达恩德培,招募了 2507 名孕妇参加一项随机、双盲、安慰剂对照试验,研究阿苯达唑和吡喹酮在 2×2 析因设计中的作用[ISRCTN32849447]。常规提供血液制剂和磺胺多辛-乙胺嘧啶用于疑似疟疾的治疗。记录产妇和围产期结局。分析按意向治疗进行。
在入组时,68%的女性有寄生虫感染,45%有钩虫感染,18%有曼氏血吸虫感染;40%的人贫血(血红蛋白水平<11.2g/dL)。分娩时,35%的人贫血;阿苯达唑(比值比[OR],0.95;95%置信区间[CI],0.79-1.15)或吡喹酮(OR,1.00;95%CI,0.83-1.21)对母体贫血均无总体影响,但在中重度钩虫感染的女性中,阿苯达唑有一定益处(OR,0.45;95%CI,0.21-0.98;P=.15 用于交互作用)。两种驱虫治疗均未影响平均出生体重(与阿苯达唑相关的平均体重差异:-0.00kg;95%CI,-0.05 至 0.04kg;与吡喹酮相关的平均体重差异:-0.01kg;95%CI,-0.05 至 0.04kg)或低出生体重的比例。怀孕期间使用驱虫药对围产儿死亡率或先天畸形没有影响。
在我们的研究地区,寄生虫感染的流行率很高,但感染强度较低,怀孕期间使用驱虫药对母体贫血、出生体重、围产儿死亡率或先天畸形没有总体影响。阿苯达唑可能对重度钩虫感染孕妇的贫血有益,值得进一步研究。